{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:03:11Z","timestamp":1787169791168,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Of late, immunotherapy has emerged as a promising therapeutic modality for the treatment of recalcitrant and difficult to treat warts. Purified protein derivative of tuberculin (PDD) and mycobacterium w (Mw) vaccine hold promising prospects for the treatment of verruca, especially in a country like ours where a majority of the population is already sensitized to mycobacterium tuberculosis both due to disease endemicity and Bacillus Calmette-Gu\u00e9rin (BCG) vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims and Objectives:<\/jats:title>\n                    <jats:p>We aimed at evaluating the treatment outcome of intralesional PPD tuberculin and Mw vaccine in the treatment of recalcitrant extragenital warts in immunocompetent subjects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>The patients included immunocompetent subjects between the ages of 16 and 65 years with two or more extragenital warts. The patients were randomized into two groups, namely A (PPD Tuberculin) and B (Mw vaccine). In both groups, 0.1 mL of active intralesional immunogen was injected at the base of the largest wart. The doses were repeated at 4 weeks' intervals for a maximum of 5 injections. Additionally, the improvement in quality of life was measured using the Hindi-validated version of the Dermatology Quality of Life Index (DLQI) questionnaire.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Ninety-seven patients completed the study, with 46 in group A and 51 in group B. In group A, 24 (52.17%) patients had complete clearance in all warts, and in group B, 32 (62.75%) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.38). The most common adverse event in patients of group A was transient injection site erythema and swelling, whereas that in group B was mild transient fever. None of the patients showed any signs of recurrence in the ensuing follow-up period. There was a statistically significant improvement in the mean DLQI scores after treatment in both groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Both PPD Tuberculin and Mw vaccine are effective in the treatment of recalcitrant warts with minimal recurrence rate. The safety profile of PPD is superior to Mw vaccine. We suggest both to be used as first-line therapy in the treatment of difficult to treat warts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijd.ijd_521_21","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T09:08:31Z","timestamp":1649927311000},"page":"26-30","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Intralesional Purified Protein Derivative of Tuberculin Versus Intralesional Mycobacterium W Vaccine in Treatment of Recalcitrant Extragenital Warts"],"prefix":"10.4103","volume":"67","author":[{"given":"Alpana","family":"Mohta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh Kumar","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh Dutt","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakanksha","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20240829","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30","author":"Formana","year":"2012","journal-title":"Vaccine"},{"key":"R2-5-20240829","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1046\/j.1365-2133.2001.04066.x","article-title":"Guidelines for the management of cutaneous warts","volume":"144","author":"Sterling","year":"2001","journal-title":"Br J Dermatol"},{"key":"R3-5-20240829","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jaad.2018.07.003","article-title":"Intralesional immunotherapy for the treatment of warts: A network meta-analysis","volume":"80","author":"Salman","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R4-5-20240829","first-page":"55","article-title":"Development of a potent invigorator of immune responses endowed with both preventive and therapeutic properties","volume":"11","author":"Talwar","year":"2017","journal-title":"Biologics"},{"key":"R5-5-20240829","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/09546634.2015.1078871","article-title":"Intralesional immunotherapy with tuberculin Purified protein derivative (PPD) in recalcitrant wart: A randomized, placebo-controlled, double-blind clinical trial including an extra group of candidates for cryotherapy","volume":"27","author":"Amirnia","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"R6-5-20240829","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00007435-199409000-00005","article-title":"Clinical course and prognostic factors of human papillomavirus infections in men","volume":"21","author":"Hippel\u00e4inen","year":"1994","journal-title":"Sex Transm Dis"},{"key":"R7-5-20240829","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.ygyno.2007.07.076","article-title":"The spectrum and clinical sequelae of human papillomavirus infection","volume":"107","author":"Monk","year":"2007","journal-title":"Gynecol Oncol"},{"key":"R8-5-20240829","first-page":"647","article-title":"Cutaneous warts: An evidence-based approach to therapy","volume":"72","author":"Bacelieri","year":"2005","journal-title":"Am Fam Physician"},{"key":"R9-5-20240829","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1396-0296.2004.04047.x","article-title":"Therapy of cutaneous human papillomavirus infections","volume":"17","author":"Rivera","year":"2004","journal-title":"Dermatol Ther"},{"key":"R10-5-20240829","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4103\/0378-6323.79694","article-title":"Intralesional immunotherapy for the management of warts","volume":"77","author":"Chandrashekar","year":"2011","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R11-5-20240829","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1468-3083.2004.01176.x","article-title":"Intralesional tuberculin for treatment of refractory warts","volume":"19","author":"Kus","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R12-5-20240829","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/2455-3972.184103","article-title":"Tuberculin purified protein derivative immunotherapy in the treatment of viral warts","volume":"2","author":"Nimbalkar","year":"2016","journal-title":"Indian J Drugs Dermatol"},{"key":"R13-5-20240829","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4103\/0378-6323.171650","article-title":"Immunotherapy using purified protein derivative in the treatment of warts: An open uncontrolled trial","volume":"82","author":"Saoji","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R14-5-20240829","first-page":"739","article-title":"Intralesional immunotherapy using tuberculin PPD in the treatment of palmoplantar and periungual warts","volume":"3","author":"Wananukul","year":"2009","journal-title":"Asian Biomed"},{"key":"R15-5-20240829","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/j.1468-3083.2008.02719.x","article-title":"Intralesional immunotherapy with killed Mycobacterium w vaccine for the treatment of ano-genital warts: An open label pilot study","volume":"22","author":"Gupta","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R16-5-20240829","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4103\/ijdvl.IJDVL_549_18","article-title":"A double-blind, randomized controlled trial to compare the effectiveness and safety of purified protein derivative of tuberculin antigen with Mycobacterium w vaccine in the treatment of multiple viral warts","volume":"85","author":"Chandra","year":"2019","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R17-5-20240829","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/1203475415616962","article-title":"Intralesional Mycobacterium w vaccine versus cryotherapy in treatment of refractory extragenital warts: A randomized, open-label, comparative study","volume":"20","author":"Dhakar","year":"2016","journal-title":"J Cutan Med Surg"},{"key":"R18-5-20240829","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4103\/0378-6323.144145","article-title":"Intralesional immunotherapy with killed Mycobacterium indicus pranii vaccine for the treatment of extensive cutaneous warts","volume":"80","author":"Singh","year":"2014","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R19-5-20240829","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4103\/0974-2077.150740","article-title":"Intralesional immunotherapy for difficult to treat warts with Mycobacterium w vaccine","volume":"7","author":"Garg","year":"2014","journal-title":"J Cutan Aesthet Surg"},{"key":"R20-5-20240829","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jamadermatol.2013.866","article-title":"Intralesional immunotherapy with Mycobacterium w vaccine in patients with multiple cutaneous warts: Uncontrolled open study","volume":"149","author":"Meena","year":"2013","journal-title":"JAMA Dermatol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_521_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:12:55Z","timestamp":1787166775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_521_21"}},"subtitle":["A Randomized, Single-Blinded, Comparative Study"],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_521_21","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}